<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Microdeletion syndromes not detectable by conventional cytogenetic analysis have been reported to occur in approximately 5% of patients with unexplained <z:hpo ids='HP_0001249'>mental retardation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Therefore, it is essential to ensure that patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> are screened for these microdeletion syndromes </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0001249'>Mental retardation</z:hpo> syndrome multiplex ligation-dependent probe amplification (MRS-MLPA) is a new technique for measuring sequence dosages that allows for the detection of copy number changes of several microdeletion syndromes (1p36 deletion <z:e sem="disease" ids="C0175702" disease_type="Disease or Syndrome" abbrv="">syndrome, Williams</z:e> syndrome, <z:e sem="disease" ids="C0795864" disease_type="Disease or Syndrome" abbrv="">Smith-Magenis syndrome</z:e>, <z:e sem="disease" ids="C0265219" disease_type="Disease or Syndrome" abbrv="MDLS">Miller-Dieker syndrome</z:e>, <z:mp ids='MP_0002538'>DiGeorge syndrome</z:mp>, Prader-Willi/<z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome</z:e>, Alagille <z:e sem="disease" ids="C0175699" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">syndrome, Saethre-Chotzen</z:e> syndrome, and <z:e sem="disease" ids="C0175695" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Sotos syndrome</z:e>) to be processed simultaneously, thus significantly reducing the amount of laboratory work </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We assessed the performance of MLPA (MRC-Holland, The Netherlands) for the detection of microdeletion syndromes by comparing the results with those generated using FISH assays </plain></SENT>
<SENT sid="4" pm="."><plain>MLPA analysis was carried out on 12 patients with microdeletion confirmed by FISH (three <z:mp ids='MP_0002538'>DiGeorge syndrome</z:mp>, four <z:e sem="disease" ids="C0175702" disease_type="Disease or Syndrome" abbrv="">Williams syndrome</z:e>, four Prader-Willi syndrome, and one <z:e sem="disease" ids="C0265219" disease_type="Disease or Syndrome" abbrv="MDLS">Miller-Dieker syndrome</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The results of MLPA analysis showed a complete concordance with FISH in 12 patients with microdeletion syndromes </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: On the basis of these results, we conclude that MLPA is an accurate, reliable, and cost-effective alternative to FISH in the screening for microdeletion syndromes </plain></SENT>
</text></document>